transplantation -therapy that is associated with infertility and a greater risk of longterm toxic ef fects. These complications might have been avoided if such pa tients had been treated with mech lorethamine. Moreover, it is un known as yet whether salvage therapy has been successful in all patients who have had a relapse.
Almost 80% of children and adolescents with cancer can be cured with current therapy. Most of the curative treatment regimens are based on chemotherapeutic agents that have been available for decades, but some of these have recently been in short sup ply. These shortages are likely to have devastating effects on pa tients with cancer and must be prevented. T he Food and Drug Adminis tration (FDA) has completed a headtohead bioequivalence study of single doses of the generic drug Budeprion XL 300 mg (extended release bupropion hydrochloride, manufactured by Impax Labora tories and distributed by Teva Pharmaceuticals) and the brand name drug Wellbutrin XL 300 mg (Biovail). The agency has conclud ed that Budeprion XL 300 mg can not be considered therapeutically equivalent to the brandname product. We at the FDA are there fore changing our bioequivalence recommendations for extended release bupropion products and have asked other manufacturers of 300mg extendedrelease bu propion products to conduct ad ditional bioequivalence studies.
Within a year after gaining approval at the end of 2006, Budeprion XL 300 mg became the subject of intense media cover age describing adverse events in patients being treated for major depressive disorder who had switched to the generic drug from Wellbutrin XL. Approval of Bude prion XL 300 mg was based on the results of a bioequivalence study of Budeprion XL 150 mg and Wellbutrin XL 150 mg, which were extrapolated to the 300mg product. Our new data provide direct comparative pharmacoki netic analyses of the 300mg products.
According to current guidance from the FDA Center for Drug Evaluation and Research, conclu sions that two drug products are bioequivalent should reflect sig nificant agreement in pharmaco kinetic parameters such that the entire 90% confidence interval associated with the genericto reference ratio of geometric means should fall within the bioequiv alence limits of 80 to 125%. 1 Budeprion XL 300 mg did not meet these criteria in our bio equivalence study, which involved 24 healthy fasting volunteers and used a singledose crossover de sign (see graph). The extent of bupropion absorption after the administration of the generic product, as reflected in the area under the curve of the plasma concentrations plotted over time, was 86% of the absorption with the brandname product (see graph), but the corresponding 90% confidence interval was 77 to 96%. In addition, the mean peak plasma concentration (C max ) observed after the administration of Budeprion XL 300 mg was only 75% of that observed after the administration of Wellbutrin XL 300 mg (90% confidence in terval, 65 to 87). In certain study participants, the C max and the area under the plasmaconcen tration curve for Budeprion XL were less than 40% of the values with Wellbutrin XL. The C max values for hydroxybupropion, the major active metabolite of bu propion hydrochloride, also failed to meet the FDA bioequivalence criteria.
The other major difference observed between Budeprion XL 300 mg and Wellbutrin XL 300 mg was in the time to peak drug concentration in the blood (T max ) (see graph). Although FDA guid ance does not include T max as a criterion for bioequivalence of bupropion hydrochloride products, the T max for Budeprion XL (4 hours) is shorter than that for Well butrin XL (5 hours). A similar difference in T max values was also observed in the bioequivalence study of the 150mg products that was originally used for ex trapolation of data for Budeprion XL 300 mg. But because the com parative areaunderthecurve and C max values for the 150mg prod ucts fell within FDA parameters and were supported by data on the performance of the product in vitro, Budeprion XL 300 mg was approved. The use of data extrapolation for the approval of Budeprion XL 300 mg should be considered in historical context. When ap plications for generic versions of Wellbutrin XL 300 mg began to come under FDA review in 2005, more than 11 million prescrip tions for the brandname product were being written each year. Programs to develop generic bu propion products, and the requi site bioequivalence studies, were important for addressing the widespread need for the treatment of major depressive disorder. At the same time, the FDA and sponsors recognized that bupro pion conferred a doserelated risk of seizures, which the agency be lieved warranted a conservative approach to bioequivalence test ing of bupropion in healthy vol unteers. Bioequivalence studies that used only the lower strength (150 mg) reflected this conser vative approach.
After the approval of Bude prion XL, the T max disparity be tween Budeprion XL 150 mg and Wellbutrin XL 150 mg remained a source of concern. This con cern, along with the reports that began surfacing after initial mar keting of Budeprion XL 300 mg, prompted the FDA to recommend, in November 2007, that the spon sor conduct a clinical compari son with the 300mg product. The FDA believed that the most appropriate population for this study would be patients who had reported a lack of efficacy or unwanted side effects after switching from Wellbutrin XL 300 mg to Budeprion XL 300 mg; the protocol therefore stipulated the enrollment of such patients. By early 2008, the sponsor had begun preparing to conduct the recommended study. Unfortunate ly, the study was terminated be cause of an inability to enroll a sufficient number of patients who met the entry criteria.
Given continuing questions about the efficacy of the 300mg product, the FDA decided to con duct, under its own auspices, the bioequivalence study described here. Because the results indi cated that Budeprion XL 300 mg cannot be considered therapeuti cally equivalent to Wellbutrin XL 300 mg, the FDA requested that the sponsors of Budeprion XL (Impax Laboratories and Teva Pharmaceuticals) voluntarily with draw the 300mg version from the market, which they agreed to do.
The results of the FDAspon sored study have led the agency to review its approach to other 300mg extendedrelease generic bupropion products. The agency has determined that direct bio equivalence studies using the 300mg strength of the brand name and generic products are appropriate and feasible. Accord ingly, the FDA has requested that other makers of generic extended release bupropion hydrochloride (Anchen, Actavis, Watson, and Mylan) perform bioequivalence studies of their 300mg products. The agency is also updating its bioequivalence guidance for these products. As new information re garding these products becomes available, the agency will take any appropriate regulatory actions and will inform the public. Pa tients who are taking the 300mg strength of generic extended release bupropion products and have questions about their medi cation should be encouraged to speak with their health care provider.
The long delay between the ap proval of Budeprion XL 300 mg in late 2006 and the appearance of the bioequivalence results report ed here, during which the prod uct remained listed by the FDA as a generic substitute for Well butrin XL 300 mg, is problemat ic. Because of the risk of seizure associated with high doses of bu propion, the agency initially took a conservative approach to trial design. Today, the FDA has greater understanding of the risk of seizure with bupropion. At the time of the sponsor's 2007 study, some critics considered its design to be flawed. The results of the recent study by the FDA show that a design entailing the enrollment of a more accessible trial population might well have brought the bioequiv alence data to light sooner. In retrospect, the conservative approach did not provide the right conclusions re garding thera peutic equivalence in a timely manner.
We do not believe that the re sults of the FDA study should cause concern regarding the over all reliability of the agency's ap proval process for generic drugs, including the use of extrapola tion, when scientifically appro priate. Technical aspects of the Budeprion formulation may have led to the failure of extrapolation in this case. More information on this issue will be generated by the other sponsors' bioequivalence studies. The other 300mg gener ic bupropion products do not use the same technology as Bude prion. The use of extrapolation for the approval of multiple strengths of generic drugs, which incorporates sciencebased reason ing, has been generally success ful, and the FDA will continue to refine its approach to this method. The agency will also move more aggressively to per form its own studies when data are urgently needed. We wish to assure the public that drug prod ucts that are approved for gener ic use will continue to be held to high standards of quality, safety, and efficacy.
Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
